Dr. Shicheng Guo, Director of Translational Genetics at Arrowhead Pharmaceuticals and Previous Principal Scientist at Johnson and Johnson, leads the development of Janssen’s target identification and validation engine (TIDVALE) and target liability assessment enigne (TLA) to feed our discovery pipeline and to identify novel drug targets from multi-omics data. He completed his postdoc train in UW-Madison, University of California, San Diego and University of Texas Health Science Center. He obtained his Ph.D.(2009-2014) at School of Life Sciences, Fudan University. His supervisors are Li Jin, Jiucun Wang and Momiao Xiong(uthealth). The realm which he focus on now is statistical genetics and computational biology including: manifold kinds of microarray analysis, meta-analysis, genome-wide SNP, RNA, Methylation, CNV analysis based on next generation sequencing technology. In the past several years, he had participated in series of attractive research( Yan-Huang methylome project et.al), and participated in publishing several interesting papers( Nature Biotechnology, Plos Biology et al) and two DNA methylation based cancer diagnosis patents. Specially, in clinical field, he want to explore some high sensitive and specific diagnosis and prognosis biomarkers for some complex disease such as immune diseases, cancer. And then establish some high accuracy disease prediction models so that doctors can make more felicitous decision to his/her patients. 5 years Perl , R usage exprience under Ubuntu system and skilled text minning operation ensure that he can make deeply data or text analysis in biology or medical family or disease data.